High-sensitivity C-reactive Protein and Other Factors as Outcome Predictors in Acute Decompensated Heart Failure  by Chen, Chih-Wei et al.
available at http://www.tzuchimedjnl.com/
Tzu Chi Medical Journal
 TZU CHI MED J  December 2009  Vol 21  No 4
*Corresponding author. Division of Cardiology, Department of Internal Medicine, Buddhist 
Dalin Tzu Chi General Hospital, 2, Min-Sheng Road, Chiayi, Taiwan.
E-mail address: R120667@tzuchi.com.tw
© 2009 Buddhist Compassion Relief Tzu Chi Foundation
Original Article
High-sensitivity C-reactive Protein and Other Factors 
as Outcome Predictors in Acute Decompensated 
Heart Failure
Chih-Wei Chen1,2*, Yen-Hsien Lee2,3, Hung-Mei Chen4, Ying-Lung Lin5
1Division of Cardiology, Department of Internal Medicine, Buddhist Dalin Tzu Chi General Hospital, Chiayi, Taiwan
2College of Medicine, Tzu Chi University, Hualien, Taiwan
3Division of Thoracic Medicine, Department of Internal Medicine, Buddhist Dalin Tzu Chi General Hospital, Chiayi, Taiwan
4Department of Medical Education, Buddhist Dalin Tzu Chi General Hospital, Chiayi, Taiwan
5Department of Family Medicine, Buddhist Dalin Tzu Chi General Hospital, Chiayi, Taiwan
Abstract
Objective: Patients with acute decompensated heart failure (ADHF) have 
high mortality and rehospitalization rates. Although circulating levels of 
high-sensitivity C-reactive protein (hs-CRP) are an accurate prognostic factor 
in chronic heart failure, no data are available to indicate whether hs-CRP 
can predict outcomes in patients with ADHF.
Materials and Methods: We prospectively evaluated serum hs-CRP lev-
els, patient characteristics, laboratory data, medications and manage-
ment during hospitalization and two end points (inhospital mortality and 
6-month readmission rate for heart failure) in 80 patients who presented 
with ADHF.
Results: No correlation was found between initial hs-CRP at admission 
and the two end points. The result was the same for all patients after 
excluding those in whom infection was a predisposing factor for ADHF. 
Cardiogenic shock significantly predicted inhospital mortality (odds ratio 
[OR] = 15.76; 95% confidence interval [CI] = 1.8–180.06; p = 0.026). A high 
serum peak creatinine level (OR = 1.39; 95% CI = 0.98–1.98; p = 0.064) 
and ischemic heart disease as the etiology of heart failure ((OR = 2.48; 95% 
CI = 0.93–6.58; p = 0.068) could predict 6-month readmission with border-
line significance.
Conclusion: Hs-CRP may have no value as a predictor of the outcomes of 
inhospital mortality and 6-month readmission for heart failure in ADHF. 
Many clinical factors such as cardiogenic shock were found to be associ-
ated with inhospital mortality, and high serum peak creatinine levels and 
ischemic heart disease as the etiology of heart failure were found to be 
associated with 6-month readmission. Therefore, early detection of these 
high-risk groups to predict inhospital outcomes is possible. [Tzu Chi Med 
J 2009;21(4):296–301]
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1. Introduction
Heart failure is a highly prevalent disease [1] with a 
high rate of mortality and repeated admissions [2–5]. 
Extremely high inhospital and post-discharge mortal-
ity rates have been found in patients with acute de-
compensation [6,7]. A high readmission rate was also 
found after each discharge [3,4,8]. Heart failure is a 
complex clinical condition. Some data have shown 
activation of the immune system, such as elevation 
of serum interleukin-6, tumor necrosis factor-alpha 
(TNF-α) and adhesion molecules such as soluble cell 
adhesion molecules, which are involved in the patho-
genesis of congestive failure and related to the se-
verity and mortality of chronic heart failure [9–11]. 
C-reactive protein (CRP) is a powerful marker of inflam-
mation. It can predict future cardiovascular events 
and mortality in men and women [12,13] and predicts 
future mortality after acute myocardial infarction [14]. 
Pye et al found that heart failure is a cause of raised 
serum levels of CRP [15]. One study has reported that 
serum high sensitivity C reactive protein (hs-CRP) is 
elevated in chronic congestive heart failure [16]. Some 
studies have demonstrated that elevated serum hs-
CRP levels are an independent predictor of perform-
ance and clinical outcomes in chronic heart failure 
[17–19]. Recently, N-terminal pro B-type natriuretic 
peptide was shown to be a good prognostic indicator 
for acute decompensated heart failure (ADHF) [20,21]. 
It predicted inhospital or post-discharge death and 
rehospitalization in patients with ADHF [22–24]. Since 
there are no reports of a relationship between CRP and 
the outcomes of patients with ADHF, we designed a pro-
spective observation trial to evaluate this relationship. 
We also evaluated the ability of other clinical factors 
and laboratory data at admission to establish outcome 
predictions for patients presenting with ADHF.
2. Materials and methods
Patients admitted to the intensive care unit of Buddhist 
Dalin Tzu Chi General Hospital with a primary diag-
nosis of congestive heart failure with pulmonary con-
gestion or edema were enrolled in this study. After 
being admitted to the intensive care unit, we col-
lected and analyzed baseline characteristics and 
serum data including hs-CRP, troponin-I, blood urea 
nitrogen (BUN), creatinine, sodium, potassium, white 
blood cell count and hemoglobin. A series of BUN and 
creatinine levels were measured and the peak levels 
of BUN and creatinine were recorded. The etiology of 
congestive heart failure was classified as ischemic 
heart disease (IHD), dilated cardiomyopathy, valvular 
heart disease (VHD) or “others”, as judged by history, 
clinical information, laboratory data, and echocardi-
ography or cardiac catheterization. We also recorded 
any predisposing factors for ADHF including acute 
coronary syndrome, infection, arrhythmia and “others” 
(including sodium and fluid overload, poor drug com-
pliance, extreme hypertension and unknown causes) 
as judged by the staff physician. The left ventricular 
ejection fraction was obtained within 24 hours after 
admission with M-mode measurement or with a mod-
ified Simpson’s method if asynergic segments of the 
left ventricle were found. Other recorded data in-
cluded clinical condition during hospitalization (renal 
failure requiring hemodialysis, gastrointestinal bleed-
ing, nosocomial infection, respiratory failure requiring 
endotracheal intubation and ventilator support, and 
arrhythmia, including atrial fibrillation and ventricular 
tachycardia), medications and specific management 
including percutaneous coronary intervention and 
cardiac surgery (coronary artery bypass graft surgery 
or valvular surgery), intra-aortic balloon counterpul-
sation and extracorporeal membrane oxygenation. 
End points included inhospital mortality and rehos-
pitalization for heart failure within 6 months after 
discharge. Informed consents were obtained from 
the patients or their families, and the study protocol 
was approved by the Research Committee and the 
Institutional Review Board of Buddhist Dalin Tzu Chi 
General Hospital (B09501003).
2.1. Statistical analysis
Patient and clinical data and specific clinical out-
comes of patients with ADHF were tabulated as the 
mean, range and standard deviation for continuous 
variables and number and percentage for categorical 
factors. To identify factors that predicted outcome 
and/or determinants for inhospital death, 6-month 
rehospitalization and hospital stays, logistic regres-
sion was performed to detect factors influencing in-
hospital death and 6-month rehospitalization because 
of the binary outcomes of these two outcomes. 
Linear regression was used to detect factors influ-
encing the length of hospital stay (continuous varia-
ble). Univariate analysis was first utilized to identify 
each variable’s effect singly on the inhospital death 
rate, 6-month rehospitalization and duration of hos-
pital stay. Age was then considered a potential con-
founder for further multivariate analysis and hs-CRP 
was our main hypothesized outcome factor, both of 
which with all significant variables found in univariate 
analysis were used for multivariate analysis (unless 
severe collinearity was detected). Odds ratios, and B 
and p values with 95% confidence intervals (CI) for 
each variable were utilized to estimate the relative risk 
of inhospital death and 6-month rehospitalization by 
logistic regression. SPSS 12.0 (SPSS Inc., Chicago, IL, 
USA) was utilized for all statistical analyses and the 
significance level (p value) was set at 0.05.
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3. Results
A total of 80 patients were enrolled in our study. 
Table 1 shows baseline patient characteristics, hospi-
tal management and outcomes. The mean age of pa-
tients was 71 years. Most of the patients presented 
with renal insufficiency with an average initial serum 
BUN level (BUNi) of 30 mg/dL and a creatinine level 
of 1.8 mg/dL. Renal function in most of the patients 
deteriorated during hospitalization where the average 
peak serum BUN level (BUNp) increased to 47 mg/dL 
and creatinine level increased to 2.2 mg/dL. The av-
erage left ventricular ejection fraction was 44%. The 
mean serum hs-CRP levels at admission were 53 mg/L. 
The inhospital mortality rate was 8.8% and the average 
hospital stay was 17 days. More than one half of the 
patients (51.3%) with ADHF were readmitted within 
6 months.
Univariate analysis for inhospital mortality and 
6-month rehospitalization for heart failure by logistic 
regression demonstrated that BUNp, the difference 
between the peak and initial serum levels of BUN 
(BUNd), respiratory failure requiring intubation and 
ventilator support, and presentation with cardiogenic 
shock and dopamine use predicted inhospital mor-
tality. In addition, initial serum level of creatinine, 
peak serum level of creatinine, and ischemic heart 
disease as the etiology of heart failure predicted 
6-month rehospitalization for heart failure. Neither 
hs-CRP nor troponin-I predicted inhospital mortality 
or rehospitalization within 6 months using univariate 
analysis. After excluding those patients where infec-
tion was a predisposing factor for ADHF, there was 
no relationship between hs-CRP and the above two 
outcomes.
Univariate analysis for duration of hospital stay by 
linear regression showed that BUNi, BUNd, VHD as the 
etiology of heart failure, respiratory failure requiring 
intubation and ventilator support, gastrointestinal 
bleeding, hemodialysis, infection, and management 
with dopamine, Levophed, percutaneous coronary 
intervention, and cardiac surgery during hospitaliza-
tion predicted a longer hospital stay.
Table 2 shows the results of multivariate analysis 
for inhospital mortality by logistic regression. Only 
cardiogenic shock showed significance in predicting 
high inhospital mortality (p = 0.026).
Table 3 shows the results of multivariate analysis 
for 6-month rehospitalization for heart failure by logis-
tic regression. Only IHD as the etiology of heart failure 
and a high peak creatinine level predicted 6-month 
rehospitalization with borderline significance. Many 
factors predicted a long hospitalization, including BUNp 
(B value = 0.17; 95% CI = 0.02–0.31; p = 0.030), gas-
trointestinal bleeding during hospitalization (B value = 
12.16; 95% CI = 0.32–23.99; p = 0.044), endotracheal 
intubation during hospitalization (B value = 12.60; 
Table 1 — Baseline characteristics, inhospital manage-
ment and outcomes (n = 80)*
Age (yr) 71 ± 15 (21–97)
Gender
 Male 46 (57.5)
 Female 34 (42.5)
Body weight (kg) 57.5 ± 13.5 (29.6–102.5)
Body height (cm) 158 ± 9 (140–178)
Diabetes
 Yes 32 (40)
 No 48 (60)
Hypertension
 Yes 44 (55)
 No 36 (45)
Smoking
 Yes 36 (45)
 No 44 (55)
BUNi (mg/dL) 30 ± 17 (8–106)
BUNp (mg/dL) 47 ± 33 (12–210)
Crei (mg/dL) 1.8 ± 1.2 (0.5–7.7)
Crep (mg/dL) 2.2 ± 1.6 (0.5–7.7)
Troponin-I (mg/dL) 1.0 ± 6.0 (0–51)
WBC (×103/μL) 10.42 ± 6.04 (3.22–46.49)
Hemoglobin (g/dL) 12.0 ± 2.8 (5.2–20.1)
Sodium (mmol/L) 135 ± 4 (125–144)
Potassium (mmol/L) 4.12 ± 0.80 (2.60–6.64)
LVEF (%) 44 ± 19 (8–88)
hs-CRP (mg/L) 53 ± 57.7 (1.2–260.2)
Gastrointestinal bleeding
 Yes 14 (17.5)
 No 66 (82.5)
Hemodialysis
 Yes 5 (6.3)
 No 75 (93.8)
Endotracheal intubation
 Yes 23 (28.8)
 No 57 (71.3)
Infection
 Yes 45 (56.3)
 No 35 (43.8)
Atrial fibrillation
 Yes 37 (46.3)
 No 43 (53.8)
Ventricular tachycardia
 Yes 3 (3.8)
 No 77 (96.3)
Pulmonary congestion/edema
 Yes 80 (100)
 No 0 (0)
Cardiogenic shock
 Yes 9 (11.3)
 No 71 (88.8)
(Continued)
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95% CI = 1.84–23.35; p = 0.022), and use of dopamine 
(B value = 14.71; 95% CI = 0.82–28.60; p = 0.038).
4. Discussion
Evidence suggests that neurohormonal and immune 
mechanisms play a central role in the pathogenesis 
of congestive heart failure (CHF). The main compo-
nents thought to be relevant to the pathogenesis of 
CHF are adhesion molecules, autoantibodies, nitric 
oxide, endothelin-1 and proinflammatory cytokines 
such as interleukin-1, interleukin-6 and TNF-α [25]. 
Proinflammatory cytokines have also been implicated 
in the progression of heart failure [26]. Elevation of 
Table 1 — (Continued)
Etiology of heart failure
 IHD 42 (52.5)
 DCM 15 (18.8)
 VHD 14 (17.5)
 Others 9 (11.3)
Factors predisposing to ADHF
 ACS 35 (43.8)
 Infection 15 (18.8)
 Arrhythmia 9 (11.3)
 Others 21 (26.3)
Medications used
 Dopamine 12 (15)
 Dobutamine 22 (27.5)
 Norepinephrine 2 (2.5)
 Nitroglycerine 75 (93.8)
 Statin 10 (12.5)
 ACEI/ARB 63 (78.8)
 Beta blocker 15 (18.8)
 Spirolactone 19 (23.8)
 Aspirin/clopidogrel 48 (60)
PCI/cardiac surgery
 Yes 16 (20)
 No 64 (80)
IABP
 Yes 2 (2.5)
 No 78 (97.5)
ECMO
 Yes 1 (1.3)
 No 79 (98.8)
Inhospital mortality 7 (8.8)
6-mo rehospitalization 41 (51.3)
Hospital stay (d) 17 ± 23 (1–180)
*Data presented as mean ± standard deviation (range) or n (%). 
BUNi = initial blood urea nitrogen; BUNp = peak blood urea nitrogen; 
Crei = initial creatinine; Crep = peak creatinine; WBC = white blood 
cell; LVEF = left ventricular ejection fraction; hs-CRP = high-sensitivity 
C-reactive protein; IHD = ischemic heart disease; DCM = dilated cardi-
omyopathy; VHD = valvular heart disease; ADHF = acute decompen-
sated heart failure; ACS = acute coronary syndrome; ACEI = angiotensin 
converting enzyme inhibitor; ARB = angiotensin receptor blocker; 
PCI = percutaneous coronary intervention; IABP = intra-aortic balloon 
counterpulsation; ECMO = extracorporeal membrane oxygenation.
Table 2 — Multivariate analyses of logistic regressions 
on inhospital mortality for patients with acute decom-
pensated heart failure (n = 80)
Variable OR 95% CI p
Age (yr) 1.07 0.98–1.16 0.16
BUNp (mg/dL) 0.76 0.33–1.74 0.52
Use of dopamine 4.36 0.48–39.57 0.19
hs-CRP (mg/L) 1.01 0.99–1.03 0.15
Cardiogenic shock 15.76 1.38–180.06 0.026
OR = odds ratio; CI = confidence interval; BUNp = peak serum blood 
urea nitrogen level; hs-CRP = high sensitivity C-reactive protein.
Table 3 — Multivariate analyses of logistic regressions 
on 6-month rehospitalization for patients with acute 
decompensated heart failure (n = 80)
Variable OR 95% CI p
Age (yr) 0.99 0.96–1.03 0.86
Crep (mg/dL) 1.39 0.98–1.98 0.064
Etiology-IHD 2.48 0.93–6.58 0.068
hs-CRP (mg/L) 0.38 0.99–1.01 0.86
OR = odds ratio; CI = confidence interval; Crep = peak creatinine; IHD = 
ischemic heart disease; hs-CRP = high sensitivity C-reactive protein.
interleukin-6 and TNF-α in chronic heart failure pre-
dict a 24-month mortality in one study [9]. Increases 
in the level of circulating soluble cell adhesion mol-
ecules are related to the severity of chronic heart fail-
ure and composite clinical outcomes (death, heart 
transplantation or hospitalization with worsening heart 
failure) in another study [11]. CRP is an acute phase 
reactant produced in the liver. Data have suggested 
that hs-CRP is an independent predictor of mortality, 
functional limitation, 5 year-survival rate and the 
composite end points of death, heart transplantation 
and hospitalization with worsening heart failure in 
patients with chronic heart failure [18,19]. Elevation 
of serum CRP levels is also found in ADHF [27]. 
However, there is still a lack of evidence concerning 
the role of hs-CRP in ADHF. Our results show that 
there may be no relationship between serum hs-CRP 
at admission for ADHF and our two main outcomes, 
inhospital mortality and 6-month readmission. Since 
there was a high correlation between infection and 
CRP, we excluded those patients with infection as a 
predisposing factor for ADHF, and there was still no 
correlation between hs-CRP and our main outcomes. 
A previous study indicated that serum CRP levels 
predicted 24-month mortality in patients with acute 
myocardial infarction since acute coronary syndrome 
is also an inflammatory process [14]. However, we 
did not find any correlation between infection or acute 
coronary syndrome as predisposing factors for ADHF 
and our two main outcomes. This result may be be-
cause the mechanism of ADHF is very complex and 
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inflammation may play only a small role. Some studies 
have recommended measuring hs-CRP levels for risk 
assessment for patients with chronic heart failure 
[17,18]. The present study implies that routine hs-CRP 
determination in ADHF may be unnecessary.
The average hospital stay was 17 days in our series 
and the longest was 180 days. The duration of hospi-
tal stay may influence medical costs and psychologi-
cal stress in patients, their families, and even their 
physicians. This study shows that inhospital morbid-
ity, such as gastrointestinal bleeding and respiratory 
failure requiring endotracheal intubation predicted 
longer hospital stays. It is reasonable that these con-
ditions complicate the hospital course and require 
more time to treat with modalities such as blood trans-
fusion, panendoscopy and artificial ventilation. In one 
study, renal dysfunction was common among pa-
tients hospitalized with ADFH and the severity at ad-
mission correlated with outcomes such as mortality, 
length of hospital stay, and total hospitalization [28]. 
Our data also showed that BUNp correlated with the 
duration of hospital stay. Use of dopamine usually 
implies a worse hemodynamic condition and a pro-
longed hospital stay is possible. We believe that a 
shorter hospitalization in our study may not have indi-
cated a better outcome, as in cases of early mortality. 
The significance of these data needs further careful 
assessment.
Repeated hospitalization is common among chronic 
heart failure patients. A previous report showed that 
patients with heart failure were admitted to the hos-
pital 2.05 times per year and spent 27.6 days in the 
hospital each year [29]. Readmission rates after hos-
pitalization for ADHF were reported to be 21.3–68.2% 
[3,22,30]. Studies have also shown that repeated 
hospitalization increases long-term mortality in pa-
tients with CHF [31]. In our study, more than half of 
the patients admitted with ADHF were rehospitalized 
within 6 months after discharge. Philbin and DiSalvo 
developed a risk score for predicting readmission [22]. 
Positive score items included black race, Medicare or 
Medicaid insurance, home health care services after 
discharge, IHD, VHD, diabetes, renal disease, chronic 
lung disease, idiopathic cardiomyopathy, prior car-
diac surgery and use of telemetry. Higher risk scores 
predicted higher readmission rates [22]. In our series, 
only IHD as the etiology of heart failure and high peak 
creatinine levels tended to predict 6-month readmis-
sion. A previous study showed that nurse-directed 
multidisciplinary intervention can reduce rehospitali-
zation for elderly patients with congestive heart failure, 
resulting in improved quality of life and reduced total 
costs [32]. Although no factor was found to be a strong 
predictor in our study, improving post-discharge multi-
disciplinary care may be beneficial to reduce total costs 
and to improve the patients’ quality of life. Inhospital 
mortality in our study was 8.8%, which was higher 
than that in other series in which the rates were ap-
proximately 4% [24,33,34]. These previous studies 
found many clinical features that predicted inhospital 
mortality, including low blood pressure, high admis-
sion levels of BUN and creatinine, low sodium levels 
(< 132 mmol/L), dyspnea at rest and elevated heart rate 
at admission [24,33–35]. Our data only showed car-
diogenic shock to be correlated with higher inhospital 
mortality. There is no doubt that cardiogenic shock 
is a life-threatening condition and further efforts to 
prevent it may be valuable in reducing inhospital 
mortality.
5. Conclusion
Although hs-CRP is an accurate prognostic factor in 
chronic heart failure, it did not predict inhospital mor-
tality, 6-month readmission for heart failure, or dura-
tion of hospitalization in patients with ADHF in our 
study. Cardiogenic shock can predict inhospital mor-
tality. Peak serum creatinine levels and ischemic heart 
disease tended to predict 6-month readmission for 
heart failure. We ultimately need to modify these 
predictive factors to reduce inhospital mortality and 
rehospitalization of ADHF patients. The small case 
number was the greatest limitation to this study. In 
particular, it may have limited our ability to observe 
statistical significance for many variables. A large-scale 
study is required in the future.
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